Skip to content
PaperFren

How funding cuts remade animal biotech

Open paper intelligence

Myelnikov shows ABRO survived 1981 cuts by promising biotechnology—recombinant drugs in sheep milk—the path that led toward Roslin and Dolly.

Source

Cuts and the cutting edge: British science funding and the making of animal biotechnology in 1980s Edinburgh

Myelnikov D · British journal for the history of science · 2017

doi.org/10.1017/s0007087417000826Read the full paper ↗6 citationscc by

What they did

Using Roslin/BBSRC archives, press, and interviews (including Grahame Bulfield), the article traces ABRO’s ARC expansion, Rothschild customer–contractor reform, the Spinks biotechnology agenda, the 11 December 1981 cut announcement, and later hybrid AFRC/MAFF/PPL funding.

What they found

The restructure pre-dated major Thatcher agricultural cuts and expressed ARC desire to prioritise biotechnology. ABRO shifted from quantitative farm genetics to transgenic pharmaceuticals. Novel programmes could be a lifeline. Private PPL money plus remaining public support was a hybrid that later strained Roslin.

The limits

What it doesn't show

This is not a cloning protocol. Farm and staff counts are from ABRO’s 1970 profile. It does not re-run Dolly experiments.

Key terms

ABRO
Animal Breeding Research Organisation, Edinburgh (1945), ancestor of the Roslin Institute.
Customer–contractor
Rothschild’s 1972 rule that ministries commission applied research rather than scientists setting the agenda.
Spinks inquiry
1978 British review that treated biotechnology as strategically applied research needing council support.
PPL
Commercial partner whose investment, with AFRC/MAFF funds, backed ABRO’s molecular genetics.

Flashcards

1 / 11

Research intelligence for this paper

See its role on concept claims, tensions it is part of, placement history, and related discoveries.

Open paper intelligence

Quiz yourself

1 / 6

ABRO later became associated with?

Common questions

Was the 1981 ABRO cut only Thatcherism?

No. It came from ARC biotechnology priorities and pre-dated the big agricultural-science cuts.

How did ABRO answer?

By campaigning as a biotech innovator, especially pharmaceuticals in sheep milk.

What funding mix followed?

Private PPL plus continued public money: commercial proof and long-term security.

More on Laboratory science